International Top Pharmaceutical Awards

  The DNA foundation model Evo 2 has been published in the journal  Nature . Trained on the DNA of over 100,000 species across the entire tree of life, Evo 2 can identify patterns in gene sequences across disparate organisms that experimental researchers would need years to uncover. The machine learning model can accurately identify disease-causing mutations in human genes and is capable of designing new genomes that are as long as the genomes of simple bacteria. Evo 2 was developed by scientists from Arc Institute and NVIDIA, convening collaborators across Stanford University, UC Berkeley, and UC San Francisco. The model's code is publicly accessible from Arc's GitHub, and is also integrated into the NVIDIA BioNeMo framework, as part of a collaboration between Arc Institute and NVIDIA to accelerate scientific research. Arc Institute also worked with AI research lab Goodfire to develop a mechanistic interpretability visualizer that uncovers the key biologic...

   One stem cell generates 14 million tumor-killing natural killer (NK) cells in major cancer breakthrough. Scientists in China have unveiled a breakthrough way to mass-produce powerful cancer-fighting immune cells in the lab. By engineering early-stage stem cells from cord blood—rather than trying to modify mature natural killer (NK) cells—they created a streamlined process that generates enormous numbers of highly potent NK cells, including CAR-equipped versions designed to hunt specific cancers. NK cells play a critical role in the body’s early defense against viruses and cancer, along with other immune functions. Because of their natural ability to detect and destroy abnormal cells, they are an attractive tool for cancer treatment. In chimeric antigen receptor (CAR)-NK therapy, scientists equip NK cells with a lab-designed receptor (a CAR) so they can recognize a specific marker on cancer cells and attack them more precisely. Traditional CAR-NK approaches usually depend on...

  Viral infectious diseases have caused millions of deaths worldwide. Antiviral agents are critical for controlling these infections; however, an open-access database dedicated specifically to antiviral agents remains unavailable. Here, we present AntiviralDB  an expert-curated resource that compiles both approved and experimental antiviral agents with laboratory-confirmed   in vitro   activity against a broad spectrum of human viruses. These include the human immunodeficiency virus, coronaviruses, hepatitis viruses, influenza virus, respiratory syncytial virus, herpes simplex virus, varicella-zoster virus, human cytomegalovirus, human papillomavirus, dengue virus, Zika virus, Ebola virus, mpox virus, norovirus, chikungunya virus, and 16 other common or life-threatening pathogens. Each antiviral agent in the database is annotated with key information, including its molecular target,   in vitro   antiviral activity (IC 50 , EC 50 , and CC 50   across sp...

  Scientists identify a key enzyme enabling cancer cells to rapidly rewire DNA, accelerating mutations, adaptation, and treatment resistance across tumors. Visit Our Website : toppharmaceutical.org Nomination link : https://toppharmaceutical.org/award-nomination/?ecategory=Awards&rcategory=Awardee Contact us : contact@toppharmaceutical.org #Cancer #Enzyme #DNA #Mutation #Genomics #Oncology #Biology #Research #Science #Medicine #Tumor

  Three years ago, Portnoy cofounded a startup, Laguna Biotherapeutics, that worked with scientists in his University of California, Berkeley lab to eliminate the bacteria's ability to cause disease while retaining its ability to rev up production of a type of immune system cell associated with increased survival in cancer patients. These so-called  gamma delta T cells  are general-purpose killers of cancer cells or any cell infected by a pathogen—bacteria, virus, or fungus. Laguna Bio will soon ask the FDA for clearance to evaluate the therapy in children with leukemia who have received unmatched bone marrow transplants. Stanford University Medical Center doctors hope that the engineered Listeria will boost gamma delta T cells in pediatric patients and help them stave off graft-versus-host disease, fight potentially deadly infections that take advantage of a transplant patient's compromised immune system, and prevent the cancer from returning. Portnoy and his colleagues ...

  Alembic Pharmaceuticals Ltd  has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Carbidopa, Levodopa and Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75 mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg, and 50 mg/200 mg/200 mg. Carbidopa, levodopa and entacapone tablets are indicated for the treatment of Parkinson’s disease.  IPCA Laboratories  informed the exchanges that manufacturing facility at Tarapur (Maharashtra) has now received Establishment Inspection Report classifying the manufacturing facility as “Voluntary Action Indicated (VAI) and that this facility is considered to be in a minimally acceptable state of compliance with regard to current good manufacturing practice (CGMP) from the US FDA. Earlier, it  Zydus Lifescience , a leading, discovery-based, global pharmaceutical company has announced that the USFDA has granted Orphan Drug Des...